The function of A1-and A2a-adenosine receptors in the control of vascular resistance and in the modulation of light-evoked neuronal activity was investigated in the isolated perfused cat eye. The A1 agonist CCPA, the A1 antagonist CPT, the A2a agonist CGS 21680 and the A2 antagonist DMPX were used. The agents were applied intra-arterially at concentrations in the low nanomolar to micromolar range during rod-selective photic stimulation. The flow rate of perfusate, reflecting vascular resistance and the light-evoked optic nerve response (ONR) were recorded. Our results show a vasodilating effect of both A1 and A2 agonists and a vasoconstricting effect of the respective antagonists. The dose-effect relationships are suggestive, however, of an A2a receptor-mediated mechanism. The amplitude of the ONR-ON component was decreased during application of both adenosine-agonists. Analysis of the dose-effect relationships and the blockade of the CCPA-induced decrease by CPT suggests that inhibition is mediated by A1 receptors. However, CGS 21680-mediated inhibition cannot be explained by unspecific binding at A1 receptors alone and suggests the involvement of inhibitory A2a receptors.
Introduction
The purinergic nucleoside adenosine acts as an extracellular modulator of various CNS functions. Despite the ubiquity of adenosine, this nucleoside plays a specific role in the pre-and postsynaptic modulation of neuronal activity and in the regulation of metabolic functions, including vasodilation and enhancement of glycogenolysis (for review see Williams, 1989) . Different membrane receptors mediate these effects. Four receptors -subtypes have been identified and cloned so far (Meyerhof, Mü ller-Brechlin & Richter, 1991; Zhou, Li, Olah, Johnson, Stiles & Civelli, 1992; Tucker & Linden, 1993) : A1, A2a, A2b, and A3. The A1-and A2-receptors were biochemically and pharmacologically characterized (Reddington & Lee, 1991) by their inhibition and stimulation, respectively, of adenylate cyclase activity, as well as by agonist and antagonist relative potency. Furthermore, the A2 receptors are divided in low (A2b) and high affinity (A2a) subclasses.
Recent evidence suggests important functions for adenosine in the retina (Blazynski & Perez, 1991) . Previous results have shown inhibitory effects of adenosine on light-evoked neuronal activity of the cat optic nerve (Blazynski, Cohen, Frü h & Niemeyer, 1989; Niemeyer & Frueh, 1989) . The adenosine-receptor subtypes responsible for this modulation of retinal information processing are as yet unknown.
The purpose of this study was to investigate the role of the A1 and A2 adenosine receptors in the perfused cat eye. We used two specific adenosine receptors agonists (Table 1) : the A1 agonist CCPA, and the A2a agonist CGS 21680C. Two antagonists were also used (Table 2) : the A1 antagonist CPT, and the A2 antagonist DMPX. These agents have the advantage of sufficient water solubility for physiological studies, which is a prerequisite in the perfused eye with an intact bloodretina barrier. We describe the effects of these compounds on the flow rate (expressing vascular resistance) and on the optic nerve response (ONR). Table 1 Substance Supplier Name Agonists 2-Chloro-N6-cyclopentyladenosine CCPA RBI, Natick, USA A1 CGS 21680C A2a 2-p-(2-Carboxyethyl)phenethylamino-5%-N-ethylcarboxamidoadenosine hydrochloride Ciba Geigy, Summit, USA Antagonists 8-Cyclopentyl-1,3-dimethylxanthine CPT RBI, Natick, USA A1 3,7-Dimethyl-1-propargylxanthine RBI, Natick, USA A2 DMPX
Materials and methods
The experiments were conducted in accordance with the resolution on the use of animals in research of the 'Association for research in vision and ophthalmology' and, with the regulations of the cantonal veterinary authority of Zü rich. Details on the method have been published previously (Niemeyer, 1981 (Niemeyer, , 1992 Jurklies, Kaelin-Lang & Niemeyer, 1996) .
Surgery and perfusion
A total of 32 eyes from 23 female cats, about 1 year old and weighing 2.8-3.5 kg, were purchased from Ciba-Geigy, Basel, Switzerland and used in this study. After premedication with atropine sulfate (0.02 -0.04 mg/kg, s.c.), the animals were anesthetised first with an i.m. injection of ketamine hydrochloride (Ketalar, 10-20 mg/kg) and then with pentobarbital hydrochloride i.v. (Nembutal, 9-16 mg/kg; Abbott laboratory, Chicago, IL). Intubation was done after injection of gallamine triethiodide i.v. as a bolus and subsequent continuous infusion (Flaxedil, 5 -10 mg/kg). Deep anesthesia was maintained by continuous pump driven i.v. application of pentobarbital. The electrocardiogram, the transcutaneous oxygen saturation and the expiratory CO 2 were monitored continuously, and a respiration pump (model 66IA, Harvard Apparatus, South Natick, USA) was used for artificial ventilation with oxygen-enriched (30%) room air for up to 12 h. Blood oxygen saturation above 94% and tidal expiration of 3-4% CO 2 were maintained throughout anesthesia. Rectal temperature (37-39°C) was regulated by a heating pad. Sodium chloride infusion (0.9%, 10 ml/kg per h) and occasionally Macrodex 70 i.v. (6%) were used to maintain fluid-and electrolyte-balance. Fentanyl (Janssen, Baar, Switzerland, 0.05 mg bolus i.v.) was applied prior to each surgical procedure to ensure analgesia. Eyes were enucleated after atropine-and phenylephrine-induced mydriasis and under anticoagulation (Liquemin, 1000 -2000 . A corresponding amount of protamine hydrochloride (1000 -2000 U, Roche Pharma) was injected after the enucleation of the first eye. Animals were sacrificed after enucleation of the second eye by an overdose of Nembutal.
After cannulation of the ophthalmociliary artery, the eyes were perfused with oxygenated tissue culture medium with Earle's salts (TC 199, Bioconcept/ Amimed, Allschwil, Switzerland), containing also L-glutamine (200 nM), amikacin-sulfate (63.9 mM, Amikin, Bristol-Meyers Squibb AG, Baar, Switzerland) and newborn calf serum (30% v/v). The perfusate was buffered with HEPES (15 mM) and NaHCO 3 (26 mM) to a pH of 7.4 at 37°C and gassed with humidified oxycarbon (95% O 2 , 5% CO 2 ) for 25 min to reach a pO 2 of 400-450 mmHg.
The flow rate was continuously recorded via an infrared drop-interval meter with an analog voltage output. Constant hydrostatic pressure drove the perfusion system, such that changes in flow rate reflected changes in the total vascular resistance of the eye.
Stimulation and recording
The source for the light stimuli was a 150 W xenon arc lamp providing a maximum of 11.54 log quanta [scot., 507 nm] degree-2 second-1. The stimuli were applied in Maxwellian view (Gouras & Hoff, 1970) . Attenuation of the light flashes was performed with neutral density filters and narrow band chromatic filters to achieve rod-matched conditions for short and long wavelength light pulses in full dark adaptation. The duration of the stimulus was 400 ms, and the interval between stimuli was 60 s.
Light-evoked compound action potentials of the optic nerve (optic nerve response, ONR) were recorded with an Ag-AgCl suction electrode at the cut end of the nerve and with a Ag-AgCl reference electrode on the surface of the optic nerve, amplified (PARC 113, EG & G, Mü nchen, Germany), band-pass filtered from 0.02-100Hz (Krohn-Hite 3750, Tecton, Bubikon, Switzerland), fed to a digital oscilloscope (Gould digital storage oscilloscope 4050, Cleveland, OH) and to a FM magnetic tape recorder. The ONR was also registered, at expanded time-scale, on a chart recorder (Gould RS 3400) using the analog outputs of the digital oscilloscope. The filtered ONR signals and the flow signal were also fed into a computer system for data analysis and storage. This system consisted of a personal computer (IBM 486DX66), an A/D converter (LabPC+, National Instruments, Ennetbaden, Switzerland) and software created with the 'Labview for windows' graphical programming language . It allows on-line analysis of the flow rate and of the amplitude of the ONR components with trend analysis, as well as off-line analysis and plotting of the data. Pharmacologically induced changes in the amplitude of three ONR components were analysed and compared to control: the ONR-ON component (i.e. the maximal amplitude after light-onset), the plateau, and the ONR-OFF component (Fig. 4) . The configuration of the OFF-component of the ONR varies between preparations (Niemeyer, 1981) . It is therefore difficult to quantify the changes in the ONR-OFF component induced by the various agents. The ONR-ON component, in contrast, has a constant configuration at a given stimulus intensity. We have therefore only quantified the changes in the amplitude of the ONR-ON component.
The ERG b-wave and the standing potential of the eye were also recorded to continuously monitor the functional state of the isolated eye, following a routine procedure. Drug-induced changes in these not entirely neuronal potentials are not included here for the sake of clarity (Kaelin-Lang, Jurklies & Niemeyer, 1995) .
At the beginning of the electrophysiological recordings, immediately after onset of perfusion, 20 ms red light pulses were applied every min for at least 60 min to monitor dark adaptation and in vitro steady-state responsiveness. If the ERG b-wave failed to reach a steady-state amplitude of 700-800 mV, indicating inadequate perfusion, the eye was not used for pharmacological trials.
Pharmacological trials
The following agents were used (Table 1) : 2-chloro-N6-cyclopentyladenosine (CCPA, A1 agonist), 3,7-dimethyl-1-propargylxanthine (DMPX, A2 antagonist), 8-cyclopentyl-1,3-dimethylxanthine (CPT, A1 antagonist) (all from RBI, Natick, USA), 2-p-(2-car- Table 2 . CGS causes a vasodilation at lower concentrations than CCPA. At higher concentrations, no differences are seen between both agonists. Both antagonists caused a dose-related vasoconstriction at similar concentrations. The concentration ranges in this and subsequent figures are as follows: low: 1 -100 nM, medium 0.1 -1.1 mM, high: 2 -50 mM. Significant differences were seen between: (1) CCPA at medium concentration and CCPA at high concentration (P= 0.0012), also there were significant differences between CCPA at medium concentration and CGS at medium (P =0.028) as well as CGS at high concentrations (P =0.012), suggesting involvement of different adenosine receptors; (2) significant differences were seen between CGS at low concentration and CGS at higher concentrations (P =0.015-0.03), as well as between CGS at low concentration and CCPA at high concentrations (P = 0.0016); (3) significant differences were seen between CPT at medium concentration and the agonists at medium and high concentrations (P = 0.0002 -0.045); (4) significant differences were seen between DMPX at high concentration and all the agonists groups (P B 0.0001 to P = 0.013).
boxyethyl)phenethylamino-5%-N-ethylcarboxamido adenosine hydrochloride, CGS 21680C, briefly referred to as CGS, A2a agonist (generously provided by Ciba Geigy, Summit, NJ). The compounds were dissolved in Ringer's solution. The antagonist CPT was dissolved under sonication. All substances were injected intra-arterially by pump driven syringes (Perfusor secura B. Braun, Bender & Hobein, Zü rich, Switzerland, or Harvard Apparatus 22). The effective intra-arterial concentration depended on the relationship between the injection rate and the perfusion rate. Every compound was injected at least once in isolation during a first trial in a new preparation. In subsequent trials agonists were injected before, during and after application of antagonists. The following agonist-antagonist combinations were used: CCPA and CPT, CGS and DMPX, CGS and CPT.
The signals and flow rate data recorded in the 5 min preceding the application of agents were used as control values. The mean of these data was set to 100%. The injection rate of the agents was always low enough to avoid noticeable diluting effects of the nutrients in the perfusate. Control series with injection of Ringer's solution alone at the same rate did not show any significant effects. After having reached a steady-state in the response, application of the drug was stopped, and washout was then allowed for 30-60 min. Trials without clear recovery during the washout period were observable effects in three trials (summarized as mean values in Table 2 ). CCPA never caused a vasoconstriction. The maximal increase in flow rate of the perfusate was 15%. The A2a adenosine agonist CGS (2 nM-5 mM) showed a similar reversible vasodilation in 23 of a total of 24 trials. In one trial CGS did not show any effects. The maximal increase in flow rate was 14%. Like CCPA, it never caused a vasoconstriction. The CGS effect was reversible.
Comparison in the dose-effects relationship between both substances reveals that CGS acted already at concentration below 100 nM (flow increase of 2.7%), whereas the A1 agonist CCPA induced no observable response (Fig. 1) . In the 'medium' range, CGS caused an increase of 6.8% and CCPA of 2.7% ( Table 2) . The difference between them was statistically significant (Fig. 2) . At 'higher' micromolar concentrations, the effects of both substances were similar: CGS induced an increase of 6.5% and CCPA of 8.3% (Table 2 and Fig.  2) .
The A1-antagonist CPT (0.1-3 mM) induced a decrease in flow rate, indicating vasoconstriction, in three out of five trials, and the A2-antagonist DMPX (1-30 mM) had similar effects in five of a total of seven trials (Table 2) . These effects were dose-related (Fig. 2) . The maximal observed flow decrease was 5% for both substances. These flow-decreasing effects at medium and high concentrations of antagonists were significantly different from the flow-increasing effects of agonists (Fig. 2 , for statistical details see legend of Fig. 2 ).
In few experiments (n= 3), CGS was injected during injection of CPT. The CGS-induced vasodilation was modified only at higher CPT concentrations: 100 nM and 1 mM CPT did not change the absolute observed vasodilation, and a CPT concentration of 3 mM decreased the maximal reached vasodilation (− 1%). The vasodilating effect of CGS (2 and 3.2 mM) was also modified by DMPX (21 and 30 mM) in two trials. The maximal observed flow increase was decreased by 2%. An additional effect of DMPX was a shortening of the recovery time of the CGS actions (data not shown).
Effects of adenosinergic agents on the optic ner6e action potential (ONR)
The A1 agonist CCPA induced a decrease in the amplitude of the ONR-ON component in dark adapted perfused cat eyes (Figs. 3 and 4) in eight trials out of 12 (40 nM-20 mM). The maximal effect was a decrease by 50%. At low nanomolar concentration, CCPA induced a decrease by 20% (summarized as mean values inTable 2, Fig. 5 ). In the 'medium' concentration range, the decrease in the amplitude of the ONR-ON component was similar: 21.7%. At higher concentrations, however, CCPA caused a decrease in three trials and an increase in four. The maximal increase by 300% was observed excluded from further evaluation. For statistical evaluation, the data were divided in three concentrations ranges: 'low', for intra-arterial concentrations between 1 nM and 0.1 mM, 'medium' for concentrations between 0.1 and 1.1 mM, and 'high' for concentrations between 2 and 50 mM. Due to the limited number of authorized experiments with cats, the number of trials for the attempted dose-response had to be kept at a minimum. Difference between groups with n ]3 were analyzed with ANOVA using a 'StatView'-Software. Post-hoc testing was done with Fisher PLSD. Significance level was set to P B0.05.
Results

Effects of adenosinergic agents on the flow rate of perfusate
Adenosine agonists, acting at both A1 and A2a receptors, caused an increase in the flow rate of the perfusate corresponding to a vasodilation ( Table 2) .
The A1 adenosine agonist CCPA induced a vasodilation in 14 of a total of 17 trials (40 nM -10 mM) and no Fig. 5 . Changes in normalized ONR-ON component amplitude in relation to the concentration of the agonists and of the antagonists (each column represents the mean of the effects). CCPA induced a decrease at low and medium concentrations and an increase with some variability at higher concentration. CGS induced also variable effects, but consistent and reversible decreases were observed already at low-nanomolar concentrations. CPT induced an increase in ONR-ON component amplitude whereas DMPX induced small and inconsistant effects. Significant differences were seen only between CCPA at high concentrations and: (1) CGS at medium concentrations (P =0.018); as well as (2) CGS at high concentrations. (P=0.008).
once at the highest applied concentration of 20 mM. The mean effect was an increase by 27.1% (Fig. 5) . This unusual variabilty of effects (large S.D. in Table  2 ) was observed using CCPA at high concentrations.
With the A2a agonist CGS, 26 trials with concentrations from 2 nM-50 mM were evaluated. Twenty out of a total of 26 trials showed a decrease in the ONR-ON component ( Figs. 3 and 4 ; mean values in Table  2 ). The maximal effect was a decrease by 50%. This inhibitory effect was long-lasting and revealed a slow and sometimes incomplete recovery (Fig. 3) .
In the 'low' concentration range, CGS induced a decrease by 5.8% (mean, Fig. 5 ). The variability was however high, and in two trials CGS increased the ONR-ON component amplitude. In the 'medium' concentration range, CGS induced a decrease by 25.3% (mean, Table 2 ). An increase in ONR-ON amplitude was never seen. At higher concentrations, an ONR-ON decrease by 22.5% was observed (Table 2, Fig. 5) .
A prominent feature of CGS effects on the ONR-ON component was a clear tachyphylaxis, as illustrated in Fig. 7 : the first trial in a given preparation always induced a more marked decrease than the following, and the recovery time took longer in the first trial. In contrast to CGS, repeated applications of CCPA failed to reveal tachyphylaxis in all our trials, and the recovery time was usually faster compared to that of CGS.
Despite the enhancing effect of CCPA at higher micromolar concentrations, no significant differences were seen between both agonists in the medium and low concentration range (Fig. 5 , see also legend for statistics): CCPA and CGS caused a similar decrease in the ONR-ON amplitude at low and at medium concentrations.
The A1 antagonist CPT enhanced the ONR-ON component in all four trials (Fig. 5, Table 2 ). This effect was reversible. In concentrations between 0.1 and 1 mM, the mean increase was by 1.17%, whereas a concentration of 2 mM (n = 1) increased the ONR-ON by 30% (Table 2, Fig. 5 ). The A2 antagonist DMPX (1-30 mM), in contrast, revealed no consistent effect on the ONR-ON component: we observed no effect in three, an enhancing effect in one (9%), and a decreasing effect in two (9 and 15%) out of a total of six trials (1-30 mM). No dose-effects relationship was observed in this small sample (Fig. 5) .
The depressing effects of the A1 agonist CCPA on the ONR-ON component were completely antagonized by the simultaneous injection of the A1 antagonist CPT (Fig. 6B) . Moreover, a reversible increase of 17% was observed (n= 1).
The depressant effects of the A2a agonist CGS in micromolar concentrations (2-3.2 mM) was not antagonized by CPT (n= 3). On the other hand, the A2 antagonist DMPX (15-30 mM) antagonized the effects of CGS (n=2) (Fig. 6A) . However, the observed tachyphylaxis must be taken into account. As a consequence, the control trials with CGS alone after the simultaneous injection of DMPX and CGS showed smaller effects than the previous control trial (Fig. 6A) .
Discussion
The results obtained with agonists and antagonists of adenosine provide further evidence for a physiological purinergic tone in the ocular vascular system as well as in the neuronal circuitry subserving retinal information processing.
Vascular effects
Agonists at both adenosine A1 and A2a receptors caused an increase in flow rate, and both specific antagonists exerted the opposite effects. Because the perfusion flow-rate is driven by constant hydrostatic pressure, the observed changes in flow rate reflect changes in vascular resistance of the whole isolated eye, i.e. the choroidal, ciliary and retinal vascular beds. Adenosine is known to be a potent vasodilator (first described by Drury & Szent-Gyoergyi, 1929) in the periphery as well as in the CNS (see Phillis (1989) , for review). Ocular vasodilation in response to adenosine in the perfused cat eye has been previously described (Blazynski et al., 1989) . Other studies have also demonstrated a vasodilatory action of adenosine on ocular blood flow (Portellos, Riva, Cranstoun, Petrig & Brucker, 1995) and on retinal blood vessels (Gidday & Park, 1993) . Studies in the intact eye in vivo indicate that vasodilation of the choroid accounts for most of these effects (Portellos et al., 1995) .
Based on the relative potencies of the agonists and antagonists, it was postulated that the A2 receptors mediated these effects (Portellos, et al., 1995) . The differences between the effects of CGS and of CCPA at low concentration (Fig. 2) confirm this hypothesis. Moreover, since CGS has a very low affinity for A2b receptors, the observed ocular vasodilation is probably A2a-receptor mediated. At concentrations above 1 mM, effects of both substances are similar, indicating that CCPA in higher concentration is no longer specific for A1 receptors. These findings are in accordance with binding-and functional assays (Williams, 1991) . The vasoconstrictive effects of both antagonists used here are indicative of an adenosinergic vascular tone. The fact that the A1 antagonist CPT induced a vasoconstriction at concentrations similar to those of DMPX does not speak against an A2 mediated vasodilation since the affinity of both antagonists for A2 receptors is similar, whereas CPT has a much higher affinity for the A1 receptors than DMPX (Williams, 1991) .
Effects on the optic ner6e compound action potential
As in other parts of the CNS, evidence has accumulated for a neuromodulating function of adenosine in the mammalian retina: a subpopulation of nerve cells with a high content of adenosine has been identified immunohistochemically in the retina (Braas, Zarbin & Snyder, 1987) , flicker-light and high potassium concentration have been shown to cause a release of adenosine metabolites (Perez, Ehninger, Lindströ m & Fredholm, 1986; Perez, Arner & Ehninger, 1988; Paes de Carvalho, Braas, Snyder & Adler, 1990) , specific binding sites have been localized (Blazynski, 1990) , and adenosine has been found to modify intracellular cAMP levels in the retina (Paes de Carvalho & De Mello, 1982; Blazynski, Kinscherf, Geary & Ferrendelli, 1986) . Moreover, specific A1 binding sites are expressed mostly in the inner retina, and A1 agonists inhibit adenylate cyclase (Blazynski, 1987) . Previous work from our laboratory demonstrated an inhibitory action of adenosine on the ONR as well as on maintained and light-evoked activity of retinal ganglions cells (Niemeyer & Frueh, 1989; Niemeyer, Frishmann & Macaluso, 1991) .
Our present results show that the A1-agonist CCPA at nanomolar and low micromolar concentrations causes a decrease of the amplitude of the ONR-ON component. The A1 antagonist CPT increases the ONR-ON component and is able to antagonize the effects of CCPA. It is therefore probable that A1 receptors in the inner retina are involved in the modulation of light-evoked retinal activity with an inhibitory action on the ONR-ON component. Moreover, the observed excitatory effect of CPT alone seems to indicate that the A1 receptors are tonically activated in the dark adapted cat retina.
Several studies have revealed a co-localization of adenosine uptake and of neurotransmitters such as acetylcholine, GABA, and 5-HT in retinal cells. On the other hand, glutamate and acetycholine agonists enhance the release of adenosine (Blazynski & Perez, 1991) . It is therefore possible that the observed effects on the ONR-ON reflect an A1-mediated modulation of neurotransmitter release involved in the retinal ONpathway. In Fig. 4 (top) a depressant effect of CCPA on the OFF-component of the ONR can be seen. Effects on the OFF pathway, reflected stronger in the light-adapted ONR signals have not yet been studied in detail. Results on effects of exogenous adenosine on cat retinal ganglion cells of the OFF center X-and Y-type have been observed previously (Niemeyer et al., 1991) .
At higher concentrations, the A1 agonist CCPA induced an increase in the amplitude of the ONR-ON component in several trials. The mechanism for this effect is not clear and might reflect unspecific effects outside of the physiological range. At these concentrations effects at purinergic receptors other than A1 are likely. The vasodilation may also play a role, since an increase in blood flow in the perfused cat eye increases the ONR-ON amplitude (Niemeyer, 1981) . However, other mechanisms are possible. In the rat cerebral cortex, A1 adenosine-agonists can inhibit the ischemiaevoked release of excitatory neurotransmitters at low concentration whereas they enhance the release at higher concentration (O'Regan, et al., 1992) . It has been suggested that A1-agonists at higher concentration act at excitatory A2 receptors (O'Regan, Simpson, Perkins, & Phillis, 1992) . The CCPA-induced increase in flow ( Fig. 2A) suggests such a non specific effect of CCPA at A2-receptors. However, the A2a agonist CGS mostly failed to induce an increase in the amplitude of the ONR-ON component. Therefore an A2a-receptor mediated effect of CCPA seems unlikely.
Consequently, the CCPA-induced increase in the ONR-ON component could be mediated by other excitatory adenosine receptors or by effects on the adenosine transporter, concepts that would require further investigations.
The specific A2a-adenosine agonist CGS depressed the ONR-ON component. This effect was apparent at low-nanomolar concentrations and in spite of the concomitant vasodilation, which per se should enhance the ONR-ON component. This competitive enhancement of neuronal activity, induced by vasodilation, could explain the rarely observed increase in ONR-ON amplitude at low concentrations, since the vascular receptors would probably be reached before the neuronal.
The CGS-induced neuronal inhibition was antagonized by DMPX, but not by CPT. These results suggest that the inhibitory effects of CGS are not mediated by inhibitory A1 receptors, but possibly by A2 receptors. In contrast to CPT, DMPX alone failed to induce clear effects, suggesting that A2 receptors are not tonically involved in the modulation of the ONR-ON.
A similar depressant action of CGS has also been observed in cortical neurons (Lin & Phillis 1991) . It was suggested that CGS acts on inhibitory A2 receptors, and that the inhibitory effect of adenosine is mediated by A1 as well as by A2 receptors (Lin & Phillis 1991) .
A study with CGS in hippocampal slices has suggested that the CGS-induced neuronal inhibition is mediated by the A1 receptors (Lupica, Wayne, Zahniser & Dunwiddie, 1990) The anticonvulsant effects of CGS in the prepiriform cortex seem also to be mediated by A1 receptors (Zhang, Franklin & Murray, 1994) . Although in our study it is possible that CGS acts in part through A1 receptors, our results suggest that the inhibitory effects of CGS in the retina are not only mediated by A1 receptors. First, the A1 antagonist CPT failed to antagonize the effects of CGS, whereas it antagonizes the effects of the A1 agonist CCPA. Second, CGS exhibited inhibitory actions in nanomolar concentration range at which an A1 effect is unlikely. Moreover, the permeability of the blood-retina barrier for CGS is low (communication from Ciba Geigy) such that the retinal interstitial concentration was probably Fig. 7 . Example of the loss of efficacy with repeated applications of 2 mM CGS. Ordinate: inhibitory effect on ONR-ON amplitude in per cent. Abscissa: first, second and third consecutive trials performed at intervals of :60 min. The five trials with CGS were done using both eyes from the same cat. much lower than the intra-arterial concentration in our trials. However, the affinity of CGS for the A3 receptors is also in the high nanomolar range (Zhou et al., 1992) , and DMPX is an A2 antagonist with low specificity. We therefore cannot exclude that CGS could act at A3 receptors.
The time-course of the effects of CGS differed from those of the A1 agonist CCPA. Pharmacokinetic factors may explain the slow recovery. However, effects of CGS in cell cultures revealed a desensitization of the A2a receptors with a rapid reduction in agonist stimulated adenyl cyclase activity, due to a decrease in receptor affinity (Palmer, Gettys, Jacobson & Stiles, 1994) . Such mechanism could explain the observed tachyphylaxis (Fig. 7) .
In conclusion, our results confirm the vasodilating function of A2 receptors and the physiological importance of A1 receptors in the inhibition of light-evoked neuronal activity in the mammalian eye. However, the adenosine agonist-induced neuronal inhibition observed in the optic nerve appears to be a complex process that can not be explained solely by A1-mediated mechanisms. Other receptors, possibly the A2a receptors, could play a role.
